Alnylam stock maintains Buy rating at H.C. Wainwright on strong TTR data
Alnylam Pharmaceuticals (NASDAQ: ALNY) has received a reaffirmed Buy rating from H.C. Wainwright, with a price target of $570.00, driven by compelling Phase 3 HELIOS-B trial data for AMVUTTRA in treating ATTR amyloidosis with cardiomyopathy (ATTR-CM). The stock, currently trading at $447.00, has surged 76% over the past year, but analysts see significant upside potential … Read more